<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35836945</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Cardiovascular Biomarkers for Prediction of in-hospital and 1-Year Post-discharge Mortality in Patients With COVID-19 Pneumonia.</ArticleTitle><Pagination><StartPage>906665</StartPage><MedlinePgn>906665</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">906665</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2022.906665</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="UNASSIGNED">While COVID-19 affects the cardiovascular system, the potential clinical impact of cardiovascular biomarkers on predicting outcomes in COVID-19 patients is still unknown. Therefore, to investigate this issue we analyzed the prognostic potential of cardiac biomarkers on in-hospital and long-term post-discharge mortality of patients with COVID-19 pneumonia.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Serum soluble ST2, VCAM-1, and hs-TnI were evaluated upon admission in 280 consecutive patients hospitalized with COVID-19-associated pneumonia in a single, tertiary care center. Patient clinical and laboratory characteristics and the concentration of biomarkers were correlated with in-hospital [Hospital stay: 11 days (10; 14)] and post-discharge all-cause mortality at 1 year follow-up [FU: 354 days (342; 361)].</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">11 patients died while hospitalized for COVID-19 (3.9%), and 11 patients died during the 1-year post-discharge follow-up period (<i>n</i> = 11, 4.1%). Using multivariate analysis, VCAM-1 was shown to predict mortality during the hospital period (HR 1.081, CI 95% 1.035;1.129, <i>p</i> = 0.017), but not ST2 or hs-TnI. In contrast, during one-year FU post hospital discharge, ST2 (HR 1.006, 95% CI 1.002;1.009, <i>p</i> &lt; 0.001) and hs-TnI (HR 1.362, 95% CI 1.050;1.766, <i>p</i> = 0.024) predicted mortality, although not VCAM-1.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">In patients hospitalized with Covid-19 pneumonia, elevated levels of VCAM-1 at admission were associated with in-hospital mortality, while ST2 and hs-TnI might predict post-discharge mortality in long term follow-up.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Motloch, Jirak, Gareeva, Davtyan, Gumerov, Lakman, Tataurov, Zulkarneev, Kabirov, Cai, Valeev, Pavlov, Kopp, Hoppe, Lichtenauer, Fiedler, Pistulli and Zagidullin.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Motloch</LastName><ForeName>Lukas J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>University Clinic for Internal Medicine II, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jirak</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University Clinic for Internal Medicine II, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gareeva</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cardiovascular Disease in COVID-19, International Research Network, Ufa, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Diseases, Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davtyan</LastName><ForeName>Paruir</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cardiovascular Disease in COVID-19, International Research Network, Ufa, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Diseases, Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gumerov</LastName><ForeName>Ruslan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cardiovascular Disease in COVID-19, International Research Network, Ufa, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Diseases, Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lakman</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Cardiovascular Disease in COVID-19, International Research Network, Ufa, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Diseases, Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Ufa State Aviation Technical University, Ufa, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scientific Laboratory for the Socio-Economic Region Problems Investigation, Bashkir State University, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tataurov</LastName><ForeName>Aleksandr</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Scientific Laboratory for the Socio-Economic Region Problems Investigation, Bashkir State University, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zulkarneev</LastName><ForeName>Rustem</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Internal Diseases, Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kabirov</LastName><ForeName>Ildar</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Urology, Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Benzhi</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Cardiovascular Disease in COVID-19, International Research Network, Ufa, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Department of Pharmacy at the Second Affiliated Hospital, and Department of Pharmacology at College of Pharmacy, Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valeev</LastName><ForeName>Bairas</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Internal Diseases, Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavlov</LastName><ForeName>Valentin</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Cardiovascular Disease in COVID-19, International Research Network, Ufa, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kopp</LastName><ForeName>Kristen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University Clinic for Internal Medicine II, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoppe</LastName><ForeName>Uta C</ForeName><Initials>UC</Initials><AffiliationInfo><Affiliation>University Clinic for Internal Medicine II, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lichtenauer</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University Clinic for Internal Medicine II, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiedler</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University Clinic for Internal Medicine II, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Cardiology, Nephrology and Intensive Care Medicine, Hospital Wiener Neustadt, Wiener Neustadt, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pistulli</LastName><ForeName>Rudin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiology I, Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Munster, Munster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zagidullin</LastName><ForeName>Naufal</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Cardiovascular Disease in COVID-19, International Research Network, Ufa, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Diseases, Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Ufa State Aviation Technical University, Ufa, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">VCAM-1</Keyword><Keyword MajorTopicYN="N">cardiovascular biomarkers</Keyword><Keyword MajorTopicYN="N">long COVID-19</Keyword><Keyword MajorTopicYN="N">post-discharge mortality</Keyword><Keyword MajorTopicYN="N">sST2</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>15</Day><Hour>2</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35836945</ArticleId><ArticleId IdType="pmc">PMC9273888</ArticleId><ArticleId IdType="doi">10.3389/fmed.2022.906665</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European society of cardiology (ESC). Eur Heart J. (2018) 39:119&#x2013;77. 10.1093/eurheartj/ehx393</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehx393</ArticleId><ArticleId IdType="pubmed">28886621</ArticleId></ArticleIdList></Reference><Reference><Citation>Zagidullin NS, Motloch LJ, Musin TI, Bagmanova ZA, Lakman IA, Tyurin AV, et al. . J-waves in acute COVID-19: a novel disease characteristic and predictor of mortality? PLoS ONE. (2021) 16:e0257982. 10.1371/journal.pone.0257982</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0257982</ArticleId><ArticleId IdType="pmc">PMC8516278</ArticleId><ArticleId IdType="pubmed">34648510</ArticleId></ArticleIdList></Reference><Reference><Citation>Gumerov RM, Gareeva DF, Davtyan PA, Rakhimova RF, Musin TI, Zagidullin SZ, et al. . Serum biomarkers of cardiovascular complications in COVID-19. Russian J Cardiol. (2021) 26:4456. (In Russ.) 10.15829/1560-4071-2021-4456</Citation><ArticleIdList><ArticleId IdType="doi">10.15829/1560-4071-2021-4456</ArticleId></ArticleIdList></Reference><Reference><Citation>Gohar A, Chong JPC, Liew OW, den Ruijter H, de Kleijn DPV, Sim D, et al. . The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction. Eur J Heart Fail. (2017) 19:1638&#x2013;47. 10.1002/ejhf.911</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.911</ArticleId><ArticleId IdType="pubmed">28849609</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. (2020) 395:1054&#x2013;62. 10.1016/S0140-6736(20)30566-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. . Association of CardiacInjury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China. JAMA Cardiol. (2020) 5:802&#x2013;10. 10.1001/jamacardio.2020.0950</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.0950</ArticleId><ArticleId IdType="pmc">PMC7097841</ArticleId><ArticleId IdType="pubmed">32211816</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019(COVID-19): evidence from a meta-analysis. Prog Cardiovasc Dis. (2020) 63:390&#x2013;1. 10.1016/j.pcad.2020.03.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcad.2020.03.001</ArticleId><ArticleId IdType="pmc">PMC7127395</ArticleId><ArticleId IdType="pubmed">32169400</ArticleId></ArticleIdList></Reference><Reference><Citation>Casula M, Montecucco F, Bonaventura A, Liberale L, Vecchi&#xe9; A, Dallegri F, et al. . Update on the role of Pentraxin 3 in atherosclerosis and cardiovascular diseases. Vasc Pharm. (2017) 99:1&#x2013;12. 10.1016/j.vph.2017.10.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vph.2017.10.003</ArticleId><ArticleId IdType="pubmed">29051088</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciccone MM, Cortese F, Gesualdo M, Riccardi R, Di Nunzio D, Moncelli M, et al. . A novel cardiac bio-marker: ST2: a review. Molecules. (2013) 18:15314&#x2013;28. 10.3390/molecules181215314</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules181215314</ArticleId><ArticleId IdType="pmc">PMC6270545</ArticleId><ArticleId IdType="pubmed">24335613</ArticleId></ArticleIdList></Reference><Reference><Citation>Zagidullin N, Motloch LJ, Gareeva D, Hamitova A, Lakman I, Krioni I, et al. . Combining novel biomarkers for risk stratification of 2-year cardiovascular mortality in patients with ST-elevation myocardial infarction. J Clin Med. (2020) 9:550. 10.3390/jcm9020550</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9020550</ArticleId><ArticleId IdType="pmc">PMC7073894</ArticleId><ArticleId IdType="pubmed">32085400</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakkar R, Lee R. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. (2008) 7:827&#x2013;40. 10.1038/nrd2660</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2660</ArticleId><ArticleId IdType="pmc">PMC4277436</ArticleId><ArticleId IdType="pubmed">18827826</ArticleId></ArticleIdList></Reference><Reference><Citation>Zizzo G, Cohen PL. Imperfect storm: is interleukin-33 the Achilles heel of COVID-19 Lancet Rheumatol. Lancet Rheumatol. (2020) 2:e779&#x2013;90. 10.1016/S2665-9913(20)30340-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30340-4</ArticleId><ArticleId IdType="pmc">PMC7546716</ArticleId><ArticleId IdType="pubmed">33073244</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y, Ge Y, Sun J. IL-33 in COVID-19: friend or foe? Cell Mol Immunol. (2021) 18:1602&#x2013;4. 10.1038/s41423-021-00685-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00685-w</ArticleId><ArticleId IdType="pmc">PMC8108013</ArticleId><ArticleId IdType="pubmed">33972738</ArticleId></ArticleIdList></Reference><Reference><Citation>Miftode RS, Petris AO, Onofrei Aursulesei V, Cianga C, Costache II, Mitu O, et al. . The novel perspectives opened by ST2 in the pandemic: a review of its role in the diagnosis and prognosis of patients with heart failure and COVID-19. Diagnostics. (2021) 11:175. 10.3390/diagnostics11020175</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics11020175</ArticleId><ArticleId IdType="pmc">PMC7911622</ArticleId><ArticleId IdType="pubmed">33530550</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng Z, Hong XY, Zhou H, Liao FL, Guo S, Li Y, et al. . Serum soluble ST2 as a novel biomarker reflecting inflammatory status and disease severity in patients with COVID-19. SSRN Electron J. (2020) 14:1619&#x2013;29. 10.2217/bmm-2020-0410</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmm-2020-0410</ArticleId><ArticleId IdType="pubmed">33336592</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-Marteles M, Rubio-Gracia J, Pe&#xf1;a-Fresneda N, Garc&#xe9;s-Horna V, Gracia-Tello B, Mart&#xed;nez-Lostao L, et al. . Early Measurement of Blood sST2 is a good predictor of death and poor outcomes in patients admitted for COVID-19 infection. J Clin Med. (2021) 10:3534. 10.3390/jcm10163534</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10163534</ArticleId><ArticleId IdType="pmc">PMC8396994</ArticleId><ArticleId IdType="pubmed">34441830</ArticleId></ArticleIdList></Reference><Reference><Citation>Jounieaux V, Basille D, Toublanc B, Andrejak C, Rodenstein DO, Mahjoub Y. Case reports: bronchial mucosal vasculature is also involved in the acute vascular distress syndrome of COVID-19. Front Med. (2021) 8:710992. 10.3389/fmed.2021.710992</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.710992</ArticleId><ArticleId IdType="pmc">PMC8669334</ArticleId><ArticleId IdType="pubmed">34917628</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahjoub Y, Rodenstein DO, Jounieaux V. Severe Covid-19 disease: rather AVDS than ARDS? Crit Care. (2020) 24:327. 10.1186/s13054-020-02972-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-02972-w</ArticleId><ArticleId IdType="pmc">PMC7288251</ArticleId><ArticleId IdType="pubmed">32527297</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bruin S, Bos LD, van Roon MA., Tuip-de Boer AM, Schuurman AR, Koel-Simmelinck MJA, et al. . Clinical features and prognostic factors in Covid-19: a prospective cohort study. Ebio Med. (2021) 67:103378. 10.1016/j.ebiom.2021.103378</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103378</ArticleId><ArticleId IdType="pmc">PMC8118723</ArticleId><ArticleId IdType="pubmed">34000622</ArticleId></ArticleIdList></Reference><Reference><Citation>Keskinidou C, Vassiliou AG, Zacharis A, Jahaj E, Gallos P, Dimopoulou I, et al. . Endothelial, immunothrombotic, and inflammatory biomarkers in the risk of mortality in critically Ill COVID-19 patients: the role of dexamethasone. Diagnostics. (2021) 1249:11. 10.3390/diagnostics11071249</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics11071249</ArticleId><ArticleId IdType="pmc">PMC8304647</ArticleId><ArticleId IdType="pubmed">34359331</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampsas S, Tsaplaris P, Pantelidis P, Oikonomou E, Marinos G, Charalambous G, et al. . The role of endothelial related circulating biomarkers in COVID-19. A systematic review and meta-analysis [published online ahead of print, 2021 Oct 26]. Curr Med Chem. (2021). 10.2174/0929867328666211026124033</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867328666211026124033</ArticleId><ArticleId IdType="pubmed">34702152</ArticleId></ArticleIdList></Reference><Reference><Citation>Russian current national COVID-19 guidelines Version 7  Available online at: https://edu.rosminzdrav.ru/fileadmin/user_upload/specialists/COVID-19/MR_COVID-19_v7.pdf; 2020 (accessed July 3, 2020).</Citation></Reference><Reference><Citation>Unified Unified digital platform - Republican Medical Information Analytical System of the Republic of Bashkortostan  Available online at: https://swantest.promedweb.ru</Citation></Reference><Reference><Citation>Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and multiorgan response. Curr Probl Cardiol. (2020) 45:100618. 10.1016/j.cpcardiol.2020.100618</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpcardiol.2020.100618</ArticleId><ArticleId IdType="pmc">PMC7187881</ArticleId><ArticleId IdType="pubmed">32439197</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z, Lei S, Zhang X, et al. . Gsslasso Cox: a Bayesian hierarchical model for predicting survival and detecting associated genes by incorporating pathway information. BMC Bioinformatics. (2019) 20:94. 10.1186/s12859-019-2656-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12859-019-2656-1</ArticleId><ArticleId IdType="pmc">PMC6391807</ArticleId><ArticleId IdType="pubmed">30813883</ArticleId></ArticleIdList></Reference><Reference><Citation>Mokhtari T, Hassani F, Ghaffari N, Ebrahimi B, Yarahmadi A, Hassanzadeh G. COVID-19 and Multiorgan Failure: A Narrative Review on Potential Mechanisms. J Mol Histol. (2020) 3:1&#x2013;16. 10.1007/s10735-020-09915-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10735-020-09915-3</ArticleId><ArticleId IdType="pmc">PMC7533045</ArticleId><ArticleId IdType="pubmed">33011887</ArticleId></ArticleIdList></Reference><Reference><Citation>Darif D, Hammi I, Kihel A, El IdrissiSaik I, Guessous F, Akarid K. The pro-inflammatory cytokines in COVID-19 pathogenesis: what goes wrong? Microb Pathog. (2021) 153:104799. 10.1016/j.micpath.2021.104799</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2021.104799</ArticleId><ArticleId IdType="pmc">PMC7889464</ArticleId><ArticleId IdType="pubmed">33609650</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R., Zinkernagel, et al. . Endothelial cell infection and endotheliitis in COVID-19. The Lancet. (2020) 395:1417&#x2013;8. 10.1016/S0140-6736(20)30937-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30937-5</ArticleId><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a de Guadiana-Romualdo L, Calvo Nieves MD, Rodr&#xed;guez Mulero MD, CalcerradaAlises I, Hern&#xe1;ndez Olivo M, TrapielloFern&#xe1;ndez W, et al. . MR-ProADM as marker of endotheliitis predicts COVID-19 severity. Eur J Clin Invest. (2021) e13511. 10.1111/eci.13511</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13511</ArticleId><ArticleId IdType="pmc">PMC7995076</ArticleId><ArticleId IdType="pubmed">33569769</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta RK, Harrison EM, Ho A, Docherty AB, Knight SR, van Smeden M, et al. . Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: A prospective cohort study. Lancet Respir Med. (2021) 9:349&#x2013;59. 10.1016/S2213-2600(20)30559-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30559-2</ArticleId><ArticleId IdType="pmc">PMC7832571</ArticleId><ArticleId IdType="pubmed">33444539</ArticleId></ArticleIdList></Reference><Reference><Citation>Guti&#xe9;rrez-Guti&#xe9;rrez B, Del Toro MD, Borobia AM, Carcas A, Jarr&#xed;n I, Yllescas M, et al. . Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: A multicentre cohort study. Lancet Infect Dis. (2021) 21:783&#x2013;92. 10.1016/S1473-3099(21)00019-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00019-0</ArticleId><ArticleId IdType="pmc">PMC7906623</ArticleId><ArticleId IdType="pubmed">33636145</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Macho J, Ryan P, Valencia J, P&#xe9;rez-Butrague&#xf1;o M, Jim&#xe9;nez E, Font&#xe1;n-Vela M, et al. . The pandemyc score. An easily applicable and interpretable model forpredicting mortality associated with COVID-19. J Clin Med. (3066) 2020:9. 10.3390/jcm9103066</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9103066</ArticleId><ArticleId IdType="pmc">PMC7598151</ArticleId><ArticleId IdType="pubmed">32977606</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497&#x2013;506. 10.1016/S0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan WJ Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. . Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. (2020) 382:1708&#x2013;20. 10.1056/NEJMoa2002032</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Jirak P, Fejzic D, Paar V, Wernly B, Pistulli R, Rohm I, et al. . Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure. Acta Pharm Sin. (2018) 39:1189&#x2013;96. 10.1038/aps.2017.167</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/aps.2017.167</ArticleId><ArticleId IdType="pmc">PMC6289366</ArticleId><ArticleId IdType="pubmed">29239349</ArticleId></ArticleIdList></Reference><Reference><Citation>Leite AR, Borges-Canha M, Cardoso R, Neves JS, Castro-Ferreira R, Leite-Moreira A. Novel biomarkers for evaluation of endothelial dysfunction. Angiology. (2020) (5):397&#x2013;410. 10.1177/0003319720903586</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0003319720903586</ArticleId><ArticleId IdType="pubmed">32077315</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong M, Jiang Y, Xia D, Xiong Y, Zheng Q, Chen F, et al. . Elevated expression of serum endothelial cell adhesion molecules in COVID-19 patients. J Infect Dis. (2020) 222:894&#x2013;8. 10.1093/infdis/jiaa349</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa349</ArticleId><ArticleId IdType="pmc">PMC7337874</ArticleId><ArticleId IdType="pubmed">32582936</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad M, Leon M, Lerman LO, Lerman A. Viral endothelial dysfunction: a unifying mechanism for COVID-19. Mayo Clin Proc. (2021) 96:3099&#x2013;108. 10.1016/j.mayocp.2021.06.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2021.06.027</ArticleId><ArticleId IdType="pmc">PMC8373818</ArticleId><ArticleId IdType="pubmed">34863398</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer W, Ulke J, Galtung N, Strasser-Marsik LC, Neuwinger N, Tauber R, et al. . Role of cell adhesion molecules for disease development of patients with and without COVID-19 in the emergency department. J Infect Dis. (2021) 223:1497&#x2013;99. 10.1093/infdis/jiab042</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab042</ArticleId><ArticleId IdType="pmc">PMC7928779</ArticleId><ArticleId IdType="pubmed">33502532</ArticleId></ArticleIdList></Reference><Reference><Citation>Bermejo-Martin JF, Gonz&#xe1;lez-Rivera M, Almansa R, Micheloud D, Tedim AP, Dom&#xed;nguez-Gil M, et al. . Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19. Crit Care Lond Engl. (2020) 1:691. 10.1186/s13054-020-03398-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03398-0</ArticleId><ArticleId IdType="pmc">PMC7734467</ArticleId><ArticleId IdType="pubmed">33317616</ArticleId></ArticleIdList></Reference><Reference><Citation>Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. (2020) 135:2033&#x2013;40. 10.1182/blood.2020006000</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020006000</ArticleId><ArticleId IdType="pmc">PMC7273827</ArticleId><ArticleId IdType="pubmed">32339221</ArticleId></ArticleIdList></Reference><Reference><Citation>Jirak P, van Almsick V, Dimitroulis D, Mirna M, Seelmaier C, Shomanova Z, et al. . Dexamethasone improves cardiovascular outcomes in critically Ill COVID-19, a real world scenario multicenter analysis. Front Med. (2022) 9:808221. 10.3389/fmed.2022.808221</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.808221</ArticleId><ArticleId IdType="pmc">PMC8847392</ArticleId><ArticleId IdType="pubmed">35186995</ArticleId></ArticleIdList></Reference><Reference><Citation>Lala A, Johnson KW, Januzzi JL, et al. . Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol. (2020) 76:533&#x2013;46. 10.1016/j.jacc.2020.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.06.007</ArticleId><ArticleId IdType="pmc">PMC7279721</ArticleId><ArticleId IdType="pubmed">32517963</ArticleId></ArticleIdList></Reference><Reference><Citation>Maino A, Di Stasio E, Grimaldi MC, Cappannoli L, Rocco E, Vergallo R, et al. . Prevalence and characteristics of myocardial injury during COVID-19 pandemic: a new role for high-sensitive troponin. Int J Cardiol. (2021) 338:278&#x2013;85. 10.1016/j.ijcard.2021.06.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2021.06.028</ArticleId><ArticleId IdType="pmc">PMC8214325</ArticleId><ArticleId IdType="pubmed">34157355</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultheiss HP, Baumeier C, Aleshcheva G, Bock CT, Escher F. Viral myocarditis-from pathophysiology to treatment. J Clin Med. (2021) 10:5240. Doi :10.3390/jcm10225240</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8623269</ArticleId><ArticleId IdType="pubmed">34830522</ArticleId></ArticleIdList></Reference><Reference><Citation>Abers MS, Delmonte OM, Ricotta EE, Fintzi J, Fink DL, de Jesus AAA, et al. . An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight. (2021) 6:144455. 10.1172/jci.insight.144455</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.144455</ArticleId><ArticleId IdType="pmc">PMC7821609</ArticleId><ArticleId IdType="pubmed">33232303</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayes-Genis A, Richards AM, Maisel AS, Mueller C, Ky B. Multimarker testing with ST2 in chronic heart failure. Am J Cardiol. (2015) 115:76B&#x2212;80B. 10.1016/j.amjcard.2015.01.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2015.01.045</ArticleId><ArticleId IdType="pubmed">25697916</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg DD, Freedman BL, Bonaca MP, Jarolim P, Scirica BM, Goodrich EL, et al. . Cardiovascular biomarkers and heart failure risk in stable patients with atherothrombotic disease: a nested biomarker study from TRA 2&#xb0;P-TIMI 50. J Am Heart Assoc. (2021) 10:e018673. 10.1161/JAHA.120.018673</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.120.018673</ArticleId><ArticleId IdType="pmc">PMC8200769</ArticleId><ArticleId IdType="pubmed">33884889</ArticleId></ArticleIdList></Reference><Reference><Citation>Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. . Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. (2018) 30:2231&#x2013;64. 10.1016/j.jacc.2018.08.1038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.08.1038</ArticleId><ArticleId IdType="pubmed">30153967</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontos MC, Turlington JS. High-sensitivity troponins in cardiovascular disease. Curr Cardiol Rep. (2020) 22:30. 10.1007/s11886-020-01279-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11886-020-01279-0</ArticleId><ArticleId IdType="pubmed">32232671</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong DH, Kim YK, Kim MR, Jang JH, Lee S. Emerging roles of vascular cell adhesion molecule-1 (VCAM-1) in immunological disorders and cancer. Int J Mol Sci. (2018) 19:1057. 10.3390/ijms19041057</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19041057</ArticleId><ArticleId IdType="pmc">PMC5979609</ArticleId><ArticleId IdType="pubmed">29614819</ArticleId></ArticleIdList></Reference><Reference><Citation>Barreiro O, Yanez-Mo M, Serrador JM, Montoya MC, Vicente-Manzanares M, Tejedor R, et al. . Dynamic interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel endothelial docking structure for adherent leukocytes. J Cell Biol. (2002) 157:1233&#x2013;45. 10.1083/jcb.200112126</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200112126</ArticleId><ArticleId IdType="pmc">PMC2173557</ArticleId><ArticleId IdType="pubmed">12082081</ArticleId></ArticleIdList></Reference><Reference><Citation>Ip C, Luk KS, Yuen VLC, et al. . Soluble suppression of tumorigenicity 2 (sST2) for predicting disease severity or mortality outcomes in cardiovascular diseases: a systematic review and meta-analysis. Int J Cardiol Heart Vasc. (2021) 37:100887. 10.1016/j.ijcha.2021.100887</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcha.2021.100887</ArticleId><ArticleId IdType="pmc">PMC8528731</ArticleId><ArticleId IdType="pubmed">34712771</ArticleId></ArticleIdList></Reference><Reference><Citation>Jirak P, Mirna M, Wernly B, Paar V, Thieme M, Betge S, et al. . Analysis of novel cardiovascular biomarkers in patients with peripheral artery disease. Minerva Med. (2018) 109:443&#x2013;50. 10.23736/S0026-4806.18.05628-8</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/S0026-4806.18.05628-8</ArticleId><ArticleId IdType="pubmed">29652038</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirna M, Rohm I, Jirak P, Wernly B, B&#xe4;z L, Paar V, et al. . Analysis of novel cardiovascular biomarkers in patients with pulmonary hypertension (PH). Heart Lung Circ. (2020) 29:337&#x2013;44. 10.1016/j.hlc.2019.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hlc.2019.03.004</ArticleId><ArticleId IdType="pubmed">31327702</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>